High-Resolution Magic-Angle-Spinning NMR in Revealing Hepatoblastoma Hallmarks
Carregando...
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
TASIC, Ljubica
AVRAMOVIC, Natasa
JADRANIN, Milka
QUINTERO, Melissa
STANISIC, Danijela
MARTINS, Lucas G. G.
COSTA, Tassia Brena Barroso Carneiro
RIVAS, Maria
Citação
BIOMEDICINES, v.10, n.12, article ID 3091, 11p, 2022
Resumo
Cancer is one of the leading causes of death in children and adolescents worldwide; among the types of liver cancer, hepatoblastoma (HBL) is the most common in childhood. Although it affects only two to three individuals in a million, it is mostly asymptomatic at diagnosis, so by the time it is detected it has already advanced. There are specific recommendations regarding HBL treatment, and ongoing studies to stratify the risks of HBL, understand the pathology, and predict prognostics and survival rates. Although magnetic resonance imaging spectroscopy is frequently used in diagnostics of HBL, high-resolution magic-angle-spinning (HR-MAS) NMR spectroscopy of HBL tissues is scarce. Using this technique, we studied the alterations among tissue metabolites of ex vivo samples from (a) HBL and non-cancer liver tissues (NCL), (b) HBL and adjacent non-tumor samples, and (c) two regions of the same HBL samples, one more centralized and the other at the edge of the tumor. It was possible to identify metabolites in HBL, then metabolites from the HBL center and the border samples, and link them to altered metabolisms in tumor tissues, highlighting their potential as biochemical markers. Metabolites closely related to liver metabolisms such as some phospholipids, triacylglycerides, fatty acids, glucose, and amino acids showed differences between the tissues.
Palavras-chave
hepatoblastoma, liver metabolome, cancer NMR-metabolomics
Referências
- Abdelahamid S., 2018, J CANC THER, V9, P793, DOI [10.4236/jct.2018.910065, DOI 10.4236/JCT.2018.910065]
- Andrisic L, 2018, REDOX BIOL, V14, P47, DOI 10.1016/j.redox.2017.08.009
- Aronson DC, 2016, SEMIN PEDIATR SURG, V25, P265, DOI 10.1053/j.sempedsurg.2016.09.002
- Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338
- Butler LM, 2020, ADV DRUG DELIVER REV, V159, P245, DOI 10.1016/j.addr.2020.07.013
- Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118
- Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002
- Chen HT, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.690641
- Crippa S, 2017, EMBO MOL MED, V9, P1589, DOI 10.15252/emmm.201707814
- Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017
- Eichenmuller M, 2014, J HEPATOL, V61, P1312, DOI [10.1016/j.jhep.2014.08.009, 10.1016/j.jhep.2014.09.016]
- Emwas AH, 2019, METABOLITES, V9, DOI 10.3390/metabo9070123
- Escobar MQ, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120843
- Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
- Johnson CH, 2016, NAT REV MOL CELL BIO, V17, P451, DOI 10.1038/nrm.2016.25
- Kalish JM, 2017, CLIN CANCER RES, V23, pE115, DOI 10.1158/1078-0432.CCR-17-0710
- Koch A, 1999, CANCER RES, V59, P269
- Le Guennec A, 2014, ANAL CHEM, V86, P5946, DOI 10.1021/ac500966e
- Lopez-Terrada D, 2009, HUM PATHOL, V40, P783, DOI 10.1016/j.humpath.2008.07.022
- Luo XJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0646-3
- Marchese S, 2018, TOXINS, V10, DOI 10.3390/toxins10110436
- Meyers RL, 2017, LANCET ONCOL, V18, P122, DOI 10.1016/S1470-2045(16)30598-8
- Pontes JGM, 2017, ANAL METHODS-UK, V9, P1078, DOI [10.1039/c6ay03102a, 10.1039/C6AY03102A]
- Escobar MQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.506959
- Rivas Maria Prates, 2020, Tumour Biol, V42, p1010428320977124, DOI 10.1177/1010428320977124
- Schmidt A, 2021, J CANCER RES CLIN, V147, P3169, DOI 10.1007/s00432-021-03713-4
- Shen G, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052-020-00877-6
- Stanisic D., 2022, TOOLS TRENDS BIOANAL, P203, DOI [10.1007/978-3-030-82381-8_9, DOI 10.1007/978-3-030-82381-8_9]
- Stephenson DJ, 2017, TRANSL RES, V189, P13, DOI 10.1016/j.trsl.2017.06.006
- Sumazin P, 2017, HEPATOLOGY, V65, P104, DOI 10.1002/hep.28888
- Takis PG, 2019, TRAC-TREND ANAL CHEM, V120, DOI 10.1016/j.trac.2018.10.036
- Ulrich EL, 2008, NUCLEIC ACIDS RES, V36, pD402, DOI 10.1093/nar/gkm957
- Wang J, 2020, INT J BIOCHEM CELL B, V125, DOI 10.1016/j.biocel.2020.105773
- Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
- Wishart DS, 2016, NAT REV DRUG DISCOV, V15, P473, DOI 10.1038/nrd.2016.32
- Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810